Skip to main content
BLA for migraine drug filed by Amgen
5/19/2017

A biologics license application has been submitted to the FDA by Amgen for its erenumab as a prevention drug for migraine. Erenumab will be co-promoted with Novartis' CGRP receptor inhibitor if approved by the agency.

Full Story: